Aqueous and vitreous penetration of linezolid (Zyvox) after oral administration

Richard G. Fiscella, Wico W. Lai, Bruce Buerk, Mona Khan, Keith A. Rodvold, Jose S Pulido, Sami Labib, Michael J. Shapiro, Norman P. Blair

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

Objective To investigate the penetration of linezolid, a synthetic oxazolidinone antibiotic, into the aqueous and vitreous humor after oral administration. Design Noncomparative interventional, prospective case series study, randomized into group 1 (dose, one 600-mg tablet) or group 2 (2 doses of 600 mg given 12 hours apart). Participants Patients undergoing pars plana vitrectomy between March 2001 and August 2002 at the University of Illinois at Chicago Eye Center who had not had prior vitrectomy surgery. Methods Aqueous, vitreous, and plasma samples were obtained and analyzed from 29 patients after oral administration of 1 dose (group 1A, 13 patients [13 eyes] sampled less than 2 hours after administration; group 1B, 9 patients [9 eyes] sampled more than 2 hours after administration) or 2 doses 12 hours apart (group 2, 7 patients [7 eyes]) before surgery. Main outcome measures Aqueous, vitreous, and plasma concentrations of linezolid (micrograms per milliliter). Results Group 1A achieved mean aqueous, vitreous, and plasma levels of 0.77±0.6 μg/mL, 0.3±0.3 μg/mL, and 5.0±3.3 μg/mL, respectively. Group 1B achieved mean aqueous, vitreous, and plasma levels of 3.8±1.2 μg/mL, 2.3±1.4 μg/mL, and 7.6±2.7 μg/mL, respectively. Group 2 achieved mean aqueous, vitreous, and plasma levels of 6.6±2.7 μg/mL, 5.7±2.7 μg/mL, and 10.3±4.1 μg/mL, respectively. Conclusions Mean inhibitory aqueous and vitreous minimum inhibitory concentrations for 90% of isolates (MIC90) were achieved against all gram-positive bacteria, including vancomycin-resistant enterococcus, methicillin-resistant Staphylococcus aureus, and streptococcal species after 2 doses given 12 hours apart. Mean MIC90 were achieved for many gram-positive pathogens after only one dose in many patients after approximately 4 hours.

Original languageEnglish (US)
Pages (from-to)1191-1195
Number of pages5
JournalOphthalmology
Volume111
Issue number6
DOIs
StatePublished - Jun 2004
Externally publishedYes

Fingerprint

Linezolid
Oral Administration
Vitrectomy
Microbial Sensitivity Tests
Oxazolidinones
Vitreous Body
Temazepam
Aqueous Humor
Gram-Positive Bacteria
Methicillin-Resistant Staphylococcus aureus
Tablets

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Fiscella, R. G., Lai, W. W., Buerk, B., Khan, M., Rodvold, K. A., Pulido, J. S., ... Blair, N. P. (2004). Aqueous and vitreous penetration of linezolid (Zyvox) after oral administration. Ophthalmology, 111(6), 1191-1195. https://doi.org/10.1016/j.ophtha.2003.09.042

Aqueous and vitreous penetration of linezolid (Zyvox) after oral administration. / Fiscella, Richard G.; Lai, Wico W.; Buerk, Bruce; Khan, Mona; Rodvold, Keith A.; Pulido, Jose S; Labib, Sami; Shapiro, Michael J.; Blair, Norman P.

In: Ophthalmology, Vol. 111, No. 6, 06.2004, p. 1191-1195.

Research output: Contribution to journalArticle

Fiscella, RG, Lai, WW, Buerk, B, Khan, M, Rodvold, KA, Pulido, JS, Labib, S, Shapiro, MJ & Blair, NP 2004, 'Aqueous and vitreous penetration of linezolid (Zyvox) after oral administration', Ophthalmology, vol. 111, no. 6, pp. 1191-1195. https://doi.org/10.1016/j.ophtha.2003.09.042
Fiscella, Richard G. ; Lai, Wico W. ; Buerk, Bruce ; Khan, Mona ; Rodvold, Keith A. ; Pulido, Jose S ; Labib, Sami ; Shapiro, Michael J. ; Blair, Norman P. / Aqueous and vitreous penetration of linezolid (Zyvox) after oral administration. In: Ophthalmology. 2004 ; Vol. 111, No. 6. pp. 1191-1195.
@article{73d6c45b4dcb4467aa500b51553968c2,
title = "Aqueous and vitreous penetration of linezolid (Zyvox) after oral administration",
abstract = "Objective To investigate the penetration of linezolid, a synthetic oxazolidinone antibiotic, into the aqueous and vitreous humor after oral administration. Design Noncomparative interventional, prospective case series study, randomized into group 1 (dose, one 600-mg tablet) or group 2 (2 doses of 600 mg given 12 hours apart). Participants Patients undergoing pars plana vitrectomy between March 2001 and August 2002 at the University of Illinois at Chicago Eye Center who had not had prior vitrectomy surgery. Methods Aqueous, vitreous, and plasma samples were obtained and analyzed from 29 patients after oral administration of 1 dose (group 1A, 13 patients [13 eyes] sampled less than 2 hours after administration; group 1B, 9 patients [9 eyes] sampled more than 2 hours after administration) or 2 doses 12 hours apart (group 2, 7 patients [7 eyes]) before surgery. Main outcome measures Aqueous, vitreous, and plasma concentrations of linezolid (micrograms per milliliter). Results Group 1A achieved mean aqueous, vitreous, and plasma levels of 0.77±0.6 μg/mL, 0.3±0.3 μg/mL, and 5.0±3.3 μg/mL, respectively. Group 1B achieved mean aqueous, vitreous, and plasma levels of 3.8±1.2 μg/mL, 2.3±1.4 μg/mL, and 7.6±2.7 μg/mL, respectively. Group 2 achieved mean aqueous, vitreous, and plasma levels of 6.6±2.7 μg/mL, 5.7±2.7 μg/mL, and 10.3±4.1 μg/mL, respectively. Conclusions Mean inhibitory aqueous and vitreous minimum inhibitory concentrations for 90{\%} of isolates (MIC90) were achieved against all gram-positive bacteria, including vancomycin-resistant enterococcus, methicillin-resistant Staphylococcus aureus, and streptococcal species after 2 doses given 12 hours apart. Mean MIC90 were achieved for many gram-positive pathogens after only one dose in many patients after approximately 4 hours.",
author = "Fiscella, {Richard G.} and Lai, {Wico W.} and Bruce Buerk and Mona Khan and Rodvold, {Keith A.} and Pulido, {Jose S} and Sami Labib and Shapiro, {Michael J.} and Blair, {Norman P.}",
year = "2004",
month = "6",
doi = "10.1016/j.ophtha.2003.09.042",
language = "English (US)",
volume = "111",
pages = "1191--1195",
journal = "Ophthalmology",
issn = "0161-6420",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Aqueous and vitreous penetration of linezolid (Zyvox) after oral administration

AU - Fiscella, Richard G.

AU - Lai, Wico W.

AU - Buerk, Bruce

AU - Khan, Mona

AU - Rodvold, Keith A.

AU - Pulido, Jose S

AU - Labib, Sami

AU - Shapiro, Michael J.

AU - Blair, Norman P.

PY - 2004/6

Y1 - 2004/6

N2 - Objective To investigate the penetration of linezolid, a synthetic oxazolidinone antibiotic, into the aqueous and vitreous humor after oral administration. Design Noncomparative interventional, prospective case series study, randomized into group 1 (dose, one 600-mg tablet) or group 2 (2 doses of 600 mg given 12 hours apart). Participants Patients undergoing pars plana vitrectomy between March 2001 and August 2002 at the University of Illinois at Chicago Eye Center who had not had prior vitrectomy surgery. Methods Aqueous, vitreous, and plasma samples were obtained and analyzed from 29 patients after oral administration of 1 dose (group 1A, 13 patients [13 eyes] sampled less than 2 hours after administration; group 1B, 9 patients [9 eyes] sampled more than 2 hours after administration) or 2 doses 12 hours apart (group 2, 7 patients [7 eyes]) before surgery. Main outcome measures Aqueous, vitreous, and plasma concentrations of linezolid (micrograms per milliliter). Results Group 1A achieved mean aqueous, vitreous, and plasma levels of 0.77±0.6 μg/mL, 0.3±0.3 μg/mL, and 5.0±3.3 μg/mL, respectively. Group 1B achieved mean aqueous, vitreous, and plasma levels of 3.8±1.2 μg/mL, 2.3±1.4 μg/mL, and 7.6±2.7 μg/mL, respectively. Group 2 achieved mean aqueous, vitreous, and plasma levels of 6.6±2.7 μg/mL, 5.7±2.7 μg/mL, and 10.3±4.1 μg/mL, respectively. Conclusions Mean inhibitory aqueous and vitreous minimum inhibitory concentrations for 90% of isolates (MIC90) were achieved against all gram-positive bacteria, including vancomycin-resistant enterococcus, methicillin-resistant Staphylococcus aureus, and streptococcal species after 2 doses given 12 hours apart. Mean MIC90 were achieved for many gram-positive pathogens after only one dose in many patients after approximately 4 hours.

AB - Objective To investigate the penetration of linezolid, a synthetic oxazolidinone antibiotic, into the aqueous and vitreous humor after oral administration. Design Noncomparative interventional, prospective case series study, randomized into group 1 (dose, one 600-mg tablet) or group 2 (2 doses of 600 mg given 12 hours apart). Participants Patients undergoing pars plana vitrectomy between March 2001 and August 2002 at the University of Illinois at Chicago Eye Center who had not had prior vitrectomy surgery. Methods Aqueous, vitreous, and plasma samples were obtained and analyzed from 29 patients after oral administration of 1 dose (group 1A, 13 patients [13 eyes] sampled less than 2 hours after administration; group 1B, 9 patients [9 eyes] sampled more than 2 hours after administration) or 2 doses 12 hours apart (group 2, 7 patients [7 eyes]) before surgery. Main outcome measures Aqueous, vitreous, and plasma concentrations of linezolid (micrograms per milliliter). Results Group 1A achieved mean aqueous, vitreous, and plasma levels of 0.77±0.6 μg/mL, 0.3±0.3 μg/mL, and 5.0±3.3 μg/mL, respectively. Group 1B achieved mean aqueous, vitreous, and plasma levels of 3.8±1.2 μg/mL, 2.3±1.4 μg/mL, and 7.6±2.7 μg/mL, respectively. Group 2 achieved mean aqueous, vitreous, and plasma levels of 6.6±2.7 μg/mL, 5.7±2.7 μg/mL, and 10.3±4.1 μg/mL, respectively. Conclusions Mean inhibitory aqueous and vitreous minimum inhibitory concentrations for 90% of isolates (MIC90) were achieved against all gram-positive bacteria, including vancomycin-resistant enterococcus, methicillin-resistant Staphylococcus aureus, and streptococcal species after 2 doses given 12 hours apart. Mean MIC90 were achieved for many gram-positive pathogens after only one dose in many patients after approximately 4 hours.

UR - http://www.scopus.com/inward/record.url?scp=2942582420&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2942582420&partnerID=8YFLogxK

U2 - 10.1016/j.ophtha.2003.09.042

DO - 10.1016/j.ophtha.2003.09.042

M3 - Article

C2 - 15177970

AN - SCOPUS:2942582420

VL - 111

SP - 1191

EP - 1195

JO - Ophthalmology

JF - Ophthalmology

SN - 0161-6420

IS - 6

ER -